Research Radar — 2026-08-31

Summary: Functional spatial transcriptomics of Ewing sarcoma identifies an invasive-front state with lower FET::ETS activity and higher LMO7 expression. Clinical, proteomic, and perturbation analyses implicate LMO7 in EMT, cytoskeletal remodeling, and metastasis.

Why it matters: The study connects a spatially localized tumor state to clinical outcome and experimentally testable metastasis biology.

Why for Yiru: It closely matches interests in spatial oncology, multimodal integration, and perturbation-linked disease-state discovery.

Summary: In esophageal squamous cell carcinoma, CSF1R inhibition removes established tumor-associated macrophages but permits complementary monocytic and granulocytic replenishment. Combined treatment with low-dose decitabine achieves sustained control across organoid xenograft, orthotopic, and immunocompetent models.

Why it matters: The treatment-resolved myeloid architecture explains a concrete route to therapeutic escape and motivates state-aware combination strategies.

Why for Yiru: Its single-cell view of immune niches and therapy response is directly useful for computational immuno-oncology.

Summary: The CMI-PB challenges benchmark 107 models predicting pertussis booster responses from pre-booster multimodal data, testing generalization on an unseen cohort and identifying immune setpoints, preprocessing, imputation, and multi-omics integration as important factors.

Why it matters: Prospective evaluation on an unseen cohort is a valuable test of whether predictive-immunology models generalize beyond training data.

Why for Yiru: The benchmark offers a transferable template for multimodal immune-response modeling and rigorous preprocessing.

Summary: AML cells use lysosomal albumin degradation as an amino-acid source, generating ammonia that is buffered by glutamate-ammonia ligase (GS/GLUL). Metabolomics, isotope tracing, and perturbation experiments identify GS capacity as a vulnerability of proteocatabolic growth.

Why it matters: The work links a measurable metabolic adaptation to a defined nitrogen-buffering dependency and tests that dependency in disease models.

Why for Yiru: It is relevant to cancer metabolism and to integrating metabolomics with perturbation and therapeutic hypotheses.

Summary: Single-cell, multi-regional profiling of fallopian tubes from 34 women, including 15 germline BRCA1/2 carriers, identifies a TP53-high secretory-cell state with replication-stress features enriched in carriers and supported by gammaH2AX and 53BP1 protein validation.

Why it matters: A carrier-enriched, genomically unstable secretory state offers a candidate early-interception signal supported by orthogonal protein measurements.

Why for Yiru: The study is a strong example of single-cell disease-state discovery with direct relevance to inherited cancer risk.

Summary: Across three public peptide-vaccine cohorts, phase-linked transcriptomic modules associate baseline immune readiness, erythroid/inflammatory signals, dendritic-cell product state, and early priming with response-related endpoints. The retrospective analyses do not establish causality, clinical utility, or durable tumor control.

Why it matters: The cautious phase-linked analysis separates response-associated layers from claims of causality, a useful discipline for retrospective immunology.

Why for Yiru: It provides a computational framework for thinking about immune readiness and vaccine-response heterogeneity.

Summary: Electron microscopy, single-cell transcriptomics, electrophysiology, and intracranial xenografts provide evidence for functional neuron-meningioma communication. Glutamatergic signaling and AMPA/NMDA receptor blockade affect proliferation, particularly in brain-invasive tumor biology.

Why it matters: The multimodal evidence supports a mechanistic link between neuronal signaling and aggressive meningioma growth, while leaving the preprint findings to further validation.

Why for Yiru: It is relevant to tumor–neuron interactions and to integrating spatial, electrophysiological, and single-cell evidence.

Summary: Integrative transcriptomic and iCLIP analyses identify PTBP1 control of a CDC42 splice switch in AML. CDC42 inhibition selectively affects leukemia cells and enhances venetoclax efficacy in the reported models.

Why it matters: The PTBP1–CDC42 mechanism links RNA regulation to leukemia fitness and suggests a combination strategy with venetoclax.

Why for Yiru: It combines transcriptomic regulation, perturbation, and therapeutic response in a computationally tractable oncology setting.